Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) is expected to issue its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect the company to post earnings of ($0.01) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 12:30 PM ET.
Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) last announced its quarterly earnings results on Thursday, August 20th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.12).
Chemomab Therapeutics Stock Performance
Shares of NASDAQ CMMB opened at $1.18 on Wednesday. Chemomab Therapeutics has a 12 month low of $0.92 and a 12 month high of $2.99. The firm has a fifty day simple moving average of $1.86 and a two-hundred day simple moving average of $1.75. The firm has a market capitalization of $8.55 million, a PE ratio of -0.55 and a beta of 0.80.
Analyst Upgrades and Downgrades
A number of equities analysts have issued reports on the company. Wall Street Zen upgraded Chemomab Therapeutics to a “hold” rating in a report on Saturday, October 3rd. Weiss Ratings raised Chemomab Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, September 16th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Chemomab Therapeutics presently has an average rating of “Reduce”.
Check Out Our Latest Report on CMMB
About Chemomab Therapeutics
Chemomab Therapeutics Ltd. is an Israel-based clinical-stage biotechnology company focused on developing therapies for diseases driven by fibrosis and inflammation. The company’s research platform is centered on chemokine biology, with the goal of developing treatments for conditions that currently have limited therapeutic options.
Chemomab’s lead product candidate is CM-101, a humanized monoclonal antibody designed to neutralize CCL24, a signaling protein believed to contribute to chronic inflammation and tissue scarring.
Further Reading
- Five stocks we like better than Chemomab Therapeutics
- Can Oil’s Big Rally Deliver Reliable Income? 3 Energy Plays to Watch
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
Receive News & Ratings for Chemomab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemomab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
